Company intelligence / Profile preview

Ectosense

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

Ectosense developed NightOwl, an FDA-approved, cloud-connected home sleep apnea test that enables convenient and accurate diagnosis of sleep apnea outside traditional clinical settings. The device has been clinically validated and adopted in several countries. In October 2021, Ectosense was acquired by ResMed to expand global access to digital sleep diagnostics.

Therapeutic areas: PulmonologyNeurology
Modalities: DeviceDigital health platform
Industry: Physiological Monitoring

Partnerships

ResMed was a minority investor before acquisition and distributed NightOwl under its own brand in some regions prior to full acquisition.

Beyond the preview

Go deeper on Ectosense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ectosense.

Explore the full profile